Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892–1868, USA.
Clin Cancer Res. 2010 Dec 1;16(23):5608-17. doi: 10.1158/1078-0432.CCR-09-1995.
Peripheral T-cell lymphomas (PTCL) constitute a group of heterogeneous diseases that are uncommon, representing, in Western countries, only approximately 10% of all non-Hodgkin lymphomas. They are typically associated with a poor prognosis compared with their B-cell counterparts and are much less well understood with respect to tumor biology, owing to their rarity and biologic heterogeneity, and to the fact that characteristic cytogenetic abnormalities are few compared with B-cell lymphomas. Although the outcome for patients with anaplastic large cell lymphoma (ALCL), particularly anaplastic lymphoma kinase (ALK)-positive ALCL, is good, other types of PTCLs are associated with a poor prognosis, even with aggressive anthracycline-based chemotherapy. In this respect, there is a need for new approaches in these diseases, and this review focuses on and explores recent experience with novel therapies in PTCL.
外周 T 细胞淋巴瘤（PTCL）是一组异质性疾病，较为罕见，在西方国家，仅占所有非霍奇金淋巴瘤的 10%左右。与 B 细胞淋巴瘤相比，它们的预后通常较差，而且由于其罕见性和生物学异质性，以及与 B 细胞淋巴瘤相比，特征性细胞遗传学异常较少，因此在肿瘤生物学方面的了解还很有限。尽管间变性大细胞淋巴瘤（ALCL）患者，特别是间变性淋巴瘤激酶（ALK）阳性 ALCL 患者的预后良好，但其他类型的 PTCL 预后较差，即使采用积极的蒽环类药物为基础的化疗也是如此。在这方面，这些疾病需要新的治疗方法，本综述重点探讨和研究了 PTCL 中新型治疗方法的最新经验。
